Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.

John Gerecitano, MD, PhD, Carol S. Portlock, MD, Paul A. Hamlin, Jr., MD, Craig H Moskowitz, MD, Ariela Noy, MD, David J. Straus, MD, Philip Schulman, MD, Otilia Dumitrescu, MD, Debra Sarasohn, MD, Jennifer Pappanicholaou, RN, Alexia Iassonos, Zhigang Zhang, Endri Horanlli, Celeste N Rojas, Andrew D. Zelenetz, MD, PhD, Owen A O'Connor, Md, PhD

Blood (2009) 114 (22): 3708.

https://doi.org/10.1182/blood.V114.22.3708.3708

Published: 2009

Journal Articles

A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

Richard M. Stone, MD, Barry Moser, PhD, Philip Schulman, MD, Robert C. Barrier, MS, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Wendy Stock, MD, Ilene A. Galinsky, NPC, Hanna Khoury, MD, Richard A. Larson, MD

Blood (2004) 104 (11): 873.

https://doi.org/10.1182/blood.V104.11.873.873

Published: 2004

Journal Articles

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA.

Rajendra N. Damle, Fabio Ghiotto, Angelo Valetto, Emilia Albesiano, Franco Fais, Xiao-Jie Yan, Cristina P. Sison, Steven L. Allen, Jonathan Kolitz, Philip Schulman, Vincent P. Vinciguerra, Petra Budde, Jurgen Frey, Kanti R. Rai, Manlio Ferrarini, Nicholas Chiorazzi

Blood (2002) 99 (11): 4087–4093.

https://doi.org/10.1182/blood.V99.11.4087

Published: 2002

Journal Articles

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

Rajendra N. Damle, Tarun Wasil, Franco Fais, Fabio Ghiotto, Angelo Valetto, Steven L. Allen, Aby Buchbinder, Daniel Budman, Klaus Dittmar, Jonathan Kolitz, Stuart M. Lichtman, Philip Schulman, Vincent P. Vinciguerra, Kanti R. Rai, Manlio Ferrarini, Nicholas Chiorazzi

Blood (1999) 94 (6): 1840–1847.

https://doi.org/10.1182/blood.V94.6.1840

Published: 1999

Journal Articles

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Richard A. Larson, Richard K. Dodge, Charles A. Linker, Richard M. Stone, Bayard L. Powell, Edward J. Lee, Philip Schulman, Frederick R. Davey, Stanley R. Frankel, Clara D. Bloomfield, Stephen L. George, Charles A. Schiffer

Blood (1998) 92 (5): 1556–1564.

https://doi.org/10.1182/blood.V92.5.1556

Published: 1998

NARROW

Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.

A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA.

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Email alerts

ASH Publications

American Society of Hematology

Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.

A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA.

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only